Zeng Xiandong, Sun Xin, He Wei, Xie Jing, Xin Caihong
Department of Oncological Surgery, Fourth People's Hospital of Shenyang, Shenyang, P.R. China.
Department of Endocrinology and Metabolism, First Affiliated Hospital of Soochow University, Suzhou, P.R. China.
BMC Endocr Disord. 2025 Jan 23;25(1):15. doi: 10.1186/s12902-025-01843-1.
Diabetes characterized by chronic hyperglycemia, has become a serious hazard to human health in the recent decades. Previous research suggests that asprosin may contribute to the development of diabetes by regulating glucose homeostasis, appetite, insulin secretion, and insulin sensitivity. Although some studies have shown that asprosin levels are higher in patients with diabetes than in healthy individuals, the association between asprosin levels and diabetes remains controversial.
This meta-analysis aimed to assess asprosin levels in patients with diabetes and in healthy individuals.
We searched the following electronic databases: Web of Science, ScienceDirect, PubMed, and Willy. The title or abstract uses the following search term: "diabetes" is used in combination with the term "asprosin." The meta-analysis results are presented as standardized mean differences (SMDs) with corresponding 95% confidence intervals (CIs).
Fourteen articles were included in this meta-analysis. In our meta-analysis, the asprosin level in patients with diabetes was significantly higher than that in healthy controls (SMD: 0.95, 95% CI [0.66, 1.24]). Moreover, there was a significant difference in the asprosin levels between patients with diabetes without complication and those with complication (SMD: 0.81, 95% CI [0.33, 1.29]).
This systematic review is the first to evaluate the relationship between asprosin levels and diabetes. The asprosin levels were significantly higher in patients with diabetes.
Not applicable.
糖尿病以慢性高血糖为特征，在近几十年已成为对人类健康的严重危害。先前的研究表明，脂肪因子可能通过调节葡萄糖稳态、食欲、胰岛素分泌和胰岛素敏感性，促进糖尿病的发展。尽管一些研究表明，糖尿病患者的脂肪因子水平高于健康个体，但脂肪因子水平与糖尿病之间的关联仍存在争议。
本荟萃分析旨在评估糖尿病患者和健康个体的脂肪因子水平。
我们检索了以下电子数据库：科学网、ScienceDirect、PubMed和Willy。标题或摘要使用以下检索词：“糖尿病”与“脂肪因子”组合使用。荟萃分析结果以标准化均数差（SMD）及其相应的95%置信区间（CI）表示。
本荟萃分析纳入了14篇文章。在我们的荟萃分析中，糖尿病患者的脂肪因子水平显著高于健康对照组（SMD：0.95，95%CI[0.66，1.24]）。此外，无并发症的糖尿病患者与有并发症的糖尿病患者之间的脂肪因子水平存在显著差异（SMD：0.81，95%CI[0.33，1.29]）。
本系统评价首次评估了脂肪因子水平与糖尿病之间的关系。糖尿病患者的脂肪因子水平显著更高。
不适用。
